A sialoglycoprotein (LEA.135) associated with favourable prognosis of patients with lymph node negative primary breast carcinoma

S. Ashraf Imam, Benjaporn Chaiwun, Michelle J. Wang, Monique M. Morris, Susan G. Groshen, A. Munro Neville, Humberto Torloni, Richard J Cote, Clive R. Taylor

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A cell-surface sialoglycoprotein (LEA.135) was identified using a monoclonal antibody that was generated by immunization of Balb/c mice with extracts of normal breast tissue following, prior immune-tolerization with mammary carcinoma cell lines. LEA.135 is distinct from other known epithelial cell-associated antigens, including the family of mucins or keratins and epidermal growth factor receptor. Using immunohistochemical; staining methods, LEA.135 expression was detected predominantly on the apical plasma membrane of normal and noeplastic mammary and extramammary epithelial cells in freshly frozen or formalin-fixed parafin-embedded tissue sections. A retrospective study of 111 cases of lymph node=negative patients (T((any)N0M0) with primary infiltrating ductal breast carcinoma. with a median follow-up of 7.9 years, was conducted. A comparison of overall survival (O.S.) was made of patients whose tumor cells exhibited reactivity with anti-LEA.135 antibody (O.S. 92.9 ± 3.3% at 8 years), compared with those whose specimens showed the absence of LEA.135 expression (O.S. 68.3 ± 10.8% at 8 years). A statistically significant univariant association between LEA.135 expression and O.S. was observed (logrank p < 0.001). In addition, in a subgroup of patients with histologically moderately differentiated tumors (N = 71), LEA.135-positive cases showed an improved O.S. (90.8 ± 4.6% at 8 years; p < 0.001 compared with those who were LEA.135-negative (O.S. 55.6 ± 13.6% at 8 years). The association remained statistically significant in a multivariable analysis after adjusting for histological grade, tumor size and age (p < 0.02). Thus, in this series of patients with lymph node-negative primary breast carcinoma, LEA.135 expression was associated with a significant decrease in the rate of recurrence and with an increase in overall survival, independent of tumor size, histologic grade, and patient's age. In contrast to the majority of other prognostic markers which predicts a worse biology, LEA.135 is a unique class of antigen whose expression indicates a lower aggressiveness of the tumor cells.

Original languageEnglish
Pages (from-to)3043-3048
Number of pages6
JournalAnticancer Research
Volume16
Issue number5 B
StatePublished - Sep 1 1996
Externally publishedYes

Fingerprint

Sialoglycoproteins
Lymph Nodes
Breast Neoplasms
Survival
Neoplasms
Breast
Epithelial Cells
Carcinoma, Ductal, Breast
Antigens
Mucins
Keratins
Epidermal Growth Factor Receptor
Formaldehyde
Immunization
Retrospective Studies
Monoclonal Antibodies
Cell Membrane
Staining and Labeling
Recurrence
Cell Line

Keywords

  • Breast carcinoma
  • Lymph node-negative
  • Prognosis
  • Sialoglycoprotein LEA.135

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Imam, S. A., Chaiwun, B., Wang, M. J., Morris, M. M., Groshen, S. G., Neville, A. M., ... Taylor, C. R. (1996). A sialoglycoprotein (LEA.135) associated with favourable prognosis of patients with lymph node negative primary breast carcinoma. Anticancer Research, 16(5 B), 3043-3048.

A sialoglycoprotein (LEA.135) associated with favourable prognosis of patients with lymph node negative primary breast carcinoma. / Imam, S. Ashraf; Chaiwun, Benjaporn; Wang, Michelle J.; Morris, Monique M.; Groshen, Susan G.; Neville, A. Munro; Torloni, Humberto; Cote, Richard J; Taylor, Clive R.

In: Anticancer Research, Vol. 16, No. 5 B, 01.09.1996, p. 3043-3048.

Research output: Contribution to journalArticle

Imam, SA, Chaiwun, B, Wang, MJ, Morris, MM, Groshen, SG, Neville, AM, Torloni, H, Cote, RJ & Taylor, CR 1996, 'A sialoglycoprotein (LEA.135) associated with favourable prognosis of patients with lymph node negative primary breast carcinoma', Anticancer Research, vol. 16, no. 5 B, pp. 3043-3048.
Imam SA, Chaiwun B, Wang MJ, Morris MM, Groshen SG, Neville AM et al. A sialoglycoprotein (LEA.135) associated with favourable prognosis of patients with lymph node negative primary breast carcinoma. Anticancer Research. 1996 Sep 1;16(5 B):3043-3048.
Imam, S. Ashraf ; Chaiwun, Benjaporn ; Wang, Michelle J. ; Morris, Monique M. ; Groshen, Susan G. ; Neville, A. Munro ; Torloni, Humberto ; Cote, Richard J ; Taylor, Clive R. / A sialoglycoprotein (LEA.135) associated with favourable prognosis of patients with lymph node negative primary breast carcinoma. In: Anticancer Research. 1996 ; Vol. 16, No. 5 B. pp. 3043-3048.
@article{0e97668635d34ac3b11f15d972df3790,
title = "A sialoglycoprotein (LEA.135) associated with favourable prognosis of patients with lymph node negative primary breast carcinoma",
abstract = "A cell-surface sialoglycoprotein (LEA.135) was identified using a monoclonal antibody that was generated by immunization of Balb/c mice with extracts of normal breast tissue following, prior immune-tolerization with mammary carcinoma cell lines. LEA.135 is distinct from other known epithelial cell-associated antigens, including the family of mucins or keratins and epidermal growth factor receptor. Using immunohistochemical; staining methods, LEA.135 expression was detected predominantly on the apical plasma membrane of normal and noeplastic mammary and extramammary epithelial cells in freshly frozen or formalin-fixed parafin-embedded tissue sections. A retrospective study of 111 cases of lymph node=negative patients (T((any)N0M0) with primary infiltrating ductal breast carcinoma. with a median follow-up of 7.9 years, was conducted. A comparison of overall survival (O.S.) was made of patients whose tumor cells exhibited reactivity with anti-LEA.135 antibody (O.S. 92.9 ± 3.3{\%} at 8 years), compared with those whose specimens showed the absence of LEA.135 expression (O.S. 68.3 ± 10.8{\%} at 8 years). A statistically significant univariant association between LEA.135 expression and O.S. was observed (logrank p < 0.001). In addition, in a subgroup of patients with histologically moderately differentiated tumors (N = 71), LEA.135-positive cases showed an improved O.S. (90.8 ± 4.6{\%} at 8 years; p < 0.001 compared with those who were LEA.135-negative (O.S. 55.6 ± 13.6{\%} at 8 years). The association remained statistically significant in a multivariable analysis after adjusting for histological grade, tumor size and age (p < 0.02). Thus, in this series of patients with lymph node-negative primary breast carcinoma, LEA.135 expression was associated with a significant decrease in the rate of recurrence and with an increase in overall survival, independent of tumor size, histologic grade, and patient's age. In contrast to the majority of other prognostic markers which predicts a worse biology, LEA.135 is a unique class of antigen whose expression indicates a lower aggressiveness of the tumor cells.",
keywords = "Breast carcinoma, Lymph node-negative, Prognosis, Sialoglycoprotein LEA.135",
author = "Imam, {S. Ashraf} and Benjaporn Chaiwun and Wang, {Michelle J.} and Morris, {Monique M.} and Groshen, {Susan G.} and Neville, {A. Munro} and Humberto Torloni and Cote, {Richard J} and Taylor, {Clive R.}",
year = "1996",
month = "9",
day = "1",
language = "English",
volume = "16",
pages = "3043--3048",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 B",

}

TY - JOUR

T1 - A sialoglycoprotein (LEA.135) associated with favourable prognosis of patients with lymph node negative primary breast carcinoma

AU - Imam, S. Ashraf

AU - Chaiwun, Benjaporn

AU - Wang, Michelle J.

AU - Morris, Monique M.

AU - Groshen, Susan G.

AU - Neville, A. Munro

AU - Torloni, Humberto

AU - Cote, Richard J

AU - Taylor, Clive R.

PY - 1996/9/1

Y1 - 1996/9/1

N2 - A cell-surface sialoglycoprotein (LEA.135) was identified using a monoclonal antibody that was generated by immunization of Balb/c mice with extracts of normal breast tissue following, prior immune-tolerization with mammary carcinoma cell lines. LEA.135 is distinct from other known epithelial cell-associated antigens, including the family of mucins or keratins and epidermal growth factor receptor. Using immunohistochemical; staining methods, LEA.135 expression was detected predominantly on the apical plasma membrane of normal and noeplastic mammary and extramammary epithelial cells in freshly frozen or formalin-fixed parafin-embedded tissue sections. A retrospective study of 111 cases of lymph node=negative patients (T((any)N0M0) with primary infiltrating ductal breast carcinoma. with a median follow-up of 7.9 years, was conducted. A comparison of overall survival (O.S.) was made of patients whose tumor cells exhibited reactivity with anti-LEA.135 antibody (O.S. 92.9 ± 3.3% at 8 years), compared with those whose specimens showed the absence of LEA.135 expression (O.S. 68.3 ± 10.8% at 8 years). A statistically significant univariant association between LEA.135 expression and O.S. was observed (logrank p < 0.001). In addition, in a subgroup of patients with histologically moderately differentiated tumors (N = 71), LEA.135-positive cases showed an improved O.S. (90.8 ± 4.6% at 8 years; p < 0.001 compared with those who were LEA.135-negative (O.S. 55.6 ± 13.6% at 8 years). The association remained statistically significant in a multivariable analysis after adjusting for histological grade, tumor size and age (p < 0.02). Thus, in this series of patients with lymph node-negative primary breast carcinoma, LEA.135 expression was associated with a significant decrease in the rate of recurrence and with an increase in overall survival, independent of tumor size, histologic grade, and patient's age. In contrast to the majority of other prognostic markers which predicts a worse biology, LEA.135 is a unique class of antigen whose expression indicates a lower aggressiveness of the tumor cells.

AB - A cell-surface sialoglycoprotein (LEA.135) was identified using a monoclonal antibody that was generated by immunization of Balb/c mice with extracts of normal breast tissue following, prior immune-tolerization with mammary carcinoma cell lines. LEA.135 is distinct from other known epithelial cell-associated antigens, including the family of mucins or keratins and epidermal growth factor receptor. Using immunohistochemical; staining methods, LEA.135 expression was detected predominantly on the apical plasma membrane of normal and noeplastic mammary and extramammary epithelial cells in freshly frozen or formalin-fixed parafin-embedded tissue sections. A retrospective study of 111 cases of lymph node=negative patients (T((any)N0M0) with primary infiltrating ductal breast carcinoma. with a median follow-up of 7.9 years, was conducted. A comparison of overall survival (O.S.) was made of patients whose tumor cells exhibited reactivity with anti-LEA.135 antibody (O.S. 92.9 ± 3.3% at 8 years), compared with those whose specimens showed the absence of LEA.135 expression (O.S. 68.3 ± 10.8% at 8 years). A statistically significant univariant association between LEA.135 expression and O.S. was observed (logrank p < 0.001). In addition, in a subgroup of patients with histologically moderately differentiated tumors (N = 71), LEA.135-positive cases showed an improved O.S. (90.8 ± 4.6% at 8 years; p < 0.001 compared with those who were LEA.135-negative (O.S. 55.6 ± 13.6% at 8 years). The association remained statistically significant in a multivariable analysis after adjusting for histological grade, tumor size and age (p < 0.02). Thus, in this series of patients with lymph node-negative primary breast carcinoma, LEA.135 expression was associated with a significant decrease in the rate of recurrence and with an increase in overall survival, independent of tumor size, histologic grade, and patient's age. In contrast to the majority of other prognostic markers which predicts a worse biology, LEA.135 is a unique class of antigen whose expression indicates a lower aggressiveness of the tumor cells.

KW - Breast carcinoma

KW - Lymph node-negative

KW - Prognosis

KW - Sialoglycoprotein LEA.135

UR - http://www.scopus.com/inward/record.url?scp=0029799644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029799644&partnerID=8YFLogxK

M3 - Article

C2 - 8920764

AN - SCOPUS:0029799644

VL - 16

SP - 3043

EP - 3048

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 B

ER -